U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 39 results

Status:
US Approved Rx (2015)
First approved in 2012

Class (Stereo):
CHEMICAL (ABSOLUTE)



Elvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor used in combination with cobicistat, emtricitabine and tenofovir alafenamid (GENVOYA®) for the treatment of HIV-1 infection in antiretroviral treatment-...
Status:
US Approved Rx (2018)
First approved in 2012

Class (Stereo):
CHEMICAL (ABSOLUTE)



Cobicistat (GS-9350) is a potent, and selective inhibitor of human cytochrome P450 3A (CYP3A) enzymes. Cobicistat is a pharmacokinetic booster of several antiretrovirals. TYBOST (cobicistat) is indicated to increase systemic exposure of atazanavir or...
Status:
US Approved Rx (2022)
First approved in 2008

Class (Stereo):
CHEMICAL (ACHIRAL)



Etravirine (formerly known as TMC125) is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor. Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immuno...
Status:
US Approved Rx (2023)
First approved in 2007

Class (Stereo):
CHEMICAL (ABSOLUTE)



Maraviroc (UK-427,857; brand-named Selzentry, or Celsentri outside the U.S) is a selective CCR5 antagonist with potent anti-human immunodeficiency virus type 1 (HIV-1) activity and favorable pharmacological properties. Maraviroc is the product of a m...
Status:
US Approved Rx (2008)
First approved in 2005

Class (Stereo):
CHEMICAL (ABSOLUTE)



Tipranavir (PNU-140690, trade mark APTIVUS) is a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. Tipranavir has potent in vitro activity against a variety of HIV-1 laboratory str...
Status:
US Approved Rx (2018)
First approved in 2003

Class (Stereo):
CHEMICAL (ABSOLUTE)



Emtricitabine was discovered by Emory researchers Dr. Dennis C. Liotta, Dr. Raymond F. Schinazi and Dr. Woo-Baeg Choi and licensed to Triangle Pharmaceuticals by Emory University in 1996. Triangle was acquired by Gilead in 2003. Emtricitabine, market...
Status:
US Approved Rx (2022)
First approved in 2000

Class (Stereo):
CHEMICAL (ABSOLUTE)



Lopinavir (ABT-378) is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir, under the trade names Kaletra.
Status:
US Approved Rx (2020)
First approved in 1998

Class (Stereo):
CHEMICAL (ABSOLUTE)



Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV in...
Status:
US Approved Rx (2024)
First approved in 1996

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ritonavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Ritonavir binds to the protease active site and inhibits the activity of the enzyme. It is FDA approved for the treatment of HIV-1 infection. In pati...
Status:
US Approved Rx (2012)
First approved in 1996

Class (Stereo):
CHEMICAL (ACHIRAL)



Nevirapine is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited ...